河北省商务厅副厅长、省自贸办副主任张记方表示，河北自贸试验区下一步将以更大力度推动京津冀自 贸试验区协同发展，重点从三方面发力：一是深化制度型开放协同，对标国际高标准经贸规则，与京津 在产权保护、金融开放等领域加大改革，力争形成协同创新成果；二是深化产业链协同，聚焦先进制 造、生物医药等重点产业，结合三地功能定位加强对接合作，破解产业协同堵点，实现资源共享；三是 深化开放通道协同，发挥三地海空港枢纽优势，构建海陆空互联互通流通体系，打造高效物流网络。 科创与产业协同 以北京为例，中国(北京)自由贸易试验区科技创新片区昌平组团，紧扣科技创新片区功能定位，以制度 创新为核心，在推动京津冀产业协同方面表现亮眼。昌平推出全国首只认股权策略行权主题基金、落地 全国首家国际研究型医院、获批全球首创"一步发酵法生物合成工艺"生产的阿洛酮糖、培育首个全球销 售额破10亿美元的国产创新药，实现多项首创突破；京津冀协同发展上，以"创新链+产业链"协同为核 心，通过签署昌津秦三地合成生物制造产业协同协议、成立京津冀合成生物制造产业创新联盟、发布技 术平台共享倡议、设立自然科学基金合作专项等，推动微元合成等企业形成"昌平总部研发、津 ...

Core Insights - The fourth joint event of the Beijing-Tianjin-Hebei Free Trade Zone was held in Tianjin, focusing on enhancing collaborative development and innovation across the entire industrial chain [1][3] - Beijing serves as the core engine for the collaborative development of the region, achieving breakthroughs in various areas such as government services, open platform construction, and regional industrial cooperation [1][3] Group 1: Achievements and Innovations - Beijing's Free Trade Zone has introduced several institutional innovations, including standardized government services and cross-border tax-free display transactions for cultural and artistic products, which have been replicated nationwide [3][4] - The three regions have collectively published 64 collaborative innovation practice cases and signed multiple strategic cooperation agreements, enhancing their collaborative efforts [4][5] Group 2: Future Directions - The focus will be on deepening institutional collaboration, aligning with international high-standard trade rules, and expanding openness in sectors like telecommunications, healthcare, and digital economy [3][5] - The regions aim to strengthen industrial chain collaboration, particularly in advanced manufacturing and biomedicine, to optimize resource allocation and achieve shared development [5][10] Group 3: Specific Initiatives - The establishment of the Beijing-Tianjin-Hebei Digital Outbound Service Alliance aims to provide digital transformation and cross-border resource matching services for enterprises in the region [4][5] - The signing of the "Beijing-Tianjin-Hebei Free Trade Zone Full Industrial Chain Collaborative Innovation Action Plan" outlines collaborative innovation paths in key industries such as advanced manufacturing, digital economy, and modern logistics [10][11]

撰文丨王聪 排版丨水成文 线粒体 （ Mitochondria ） 对于细胞能量的产生以及细胞的整体功能至关重要。 线粒体 DNA （mtDNA） 的突变可引发使人衰弱的疾病，尤其会损害肌肉和神 经细胞等高耗能组织。高精度线粒体 DNA 操作有望揭示潜在的疾病机制并提供针对性治疗方案，但要实现这种精度仍是一项重大挑战。 近几年，出现了线粒体 DNA 编辑方法，然而，这些方法通常难以实现精准的单碱基编辑，通常会产生 旁观者编辑 （ Bystander editing ） ，这成为 了线粒体 DNA 编辑技术更广泛应用的一个主要限制。 2025 年 11 月 1 7 日 ， 西湖大学生命科学学院 卢培龙 团队 和 北京大学未来技术学院/核糖核酸北京研究中心 汪阳明 团队合作 （ 米黎 、 李宇轩 、 吕莘辰 为论文共同第一作者 ） ，在 Nature 子刊 Nature Structural & Molecular Biology 上发表了题为： Computational design of a high-precision mitochondrial DNA cytosine base editor 的研究论 ...

Market Overview - Technology stocks experienced a collective pullback, with indices showing a slight V-shaped recovery [3] - The biodiesel sector saw significant gains, with stocks like Shanhigh Environmental and Jiaao Environmental hitting the daily limit [3] - Gene editing stocks surged, with companies such as Nanjing Xinbai and Jimin Health reaching their daily limits [3] - Oil service stocks also performed well, with companies like Zhun Oil and Shandong Molong hitting the daily limit [3] - The satellite internet sector saw a late-stage rally, with Shanghai Huguang and Shanghai Gangwan both experiencing sharp increases [3] Banking Sector - The banking sector showed resilience amidst the overall market decline, with major banks like Agricultural Bank of China leading the way [5] - Agricultural Bank of China saw a significant increase of 3.49%, reaching a market capitalization of over 3 trillion, solidifying its position as the second-largest bank globally [6] Satellite Internet - The satellite internet sector rebounded sharply in the late trading session, with notable gains from companies like Aerospace Zhizhuang and China Satellite [10] - The catalyst for this rally was the announcement of a new, cheaper Starlink home package by SpaceX, priced at $40 per month [10] Company-Specific Developments - Xingsen Technology experienced a rise of 6% after rumors of a partnership with Nvidia surfaced, although these claims were later disputed [12][13] - Daily Interaction saw a volatile trading session, initially declining but then surging over 10% due to speculation around a new product release related to DeepSeek [19]

IT之家 11 月 10 日消息，华尔街日报于 11 月 8 日发布博文，报道称由 OpenAI 首席执行官山姆・奥尔特曼及 Coinbase 首席执行官布莱恩・阿 姆斯特朗等科技巨头投资的初创公司 Preventive，正秘密推进一项创造"基因编辑婴儿"的计划。 奥尔特曼的丈夫奥利弗・穆尔赫林（Oliver Mulherin，两人于 2024 年 1 月结婚）表示，是他主导了这项投资，称此举旨在帮助家庭避免遗传 疾病。 阿姆斯特朗曾公开支持胚胎编辑，他发帖表示"很高兴"支持 Preventive 公司，并认为纠正胚胎中的基因缺陷比治疗成年后的疾病要容易得 多。 很高兴能成为 Preventive 的投资者! 全球有超过3亿人患有遗传性疾病。应开展基础研究，以确定能否开发出安 全有效的疗法，在出生时就治愈这些疾病。在疾病进展之前,例如在胚胎时 期,纠正少量细胞的病变要容易得多。 翻译帖子 Lucas Harrington @ @CRISPR_LuCas . 10月30日 Excited to announce Preventive, a PBC dedicated to rigorous research i ...

Group 1: Beidou Navigation Industry - The Beijing-Tianjin-Hebei region aims to promote the application of over 800,000 new Beidou independent positioning terminal products by 2027, with a total application scale reaching 5 million units [1] - The action plan targets the cultivation of 10 leading enterprises and 50 "specialized, refined, distinctive, and innovative" companies, aiming to create an industry cluster worth over 200 billion yuan [1] - Huatai Securities believes that the Beidou navigation application industry has broad prospects, driven by demand from smartphones, consumer electronics, and specialized industries [1] Group 2: Robotaxi Development - Alibaba's Gaode announced a partnership with XPeng to integrate Robotaxi services into its platform, marking a significant step in the autonomous driving sector [2] - Morgan Stanley predicts that the global Robotaxi and fully autonomous driving market could reach approximately $300 billion by 2035 [2] - CITIC Securities highlights that the smart vehicle sector is a key growth area, with expectations for a critical transition in smart driving chips by 2025 [2] Group 3: Robotics Industry - XPeng aims to achieve mass production of advanced humanoid robots by the end of 2026 and plans to open its robot SDK to global developers [3] - The humanoid robot industry is entering a phase of rapid development, with significant applications expected in industrial settings [3][5] - ByteDance's recruitment for a senior algorithm expert in humanoid robotics indicates a strong commitment to advancing in this cutting-edge field [5] Group 4: Energy Storage Market - As of September 2023, China's new energy storage installed capacity has surpassed 100 million kilowatts, growing over 30 times since the end of the 13th Five-Year Plan [4] - The global energy storage market is expanding rapidly, with domestic bidding for storage projects increasing by 30% year-on-year [4] - The transition of energy storage from a policy-driven option to a market-driven necessity is expected to drive significant growth in the sector [4] Group 5: Gene Editing and Biotechnology - United Therapeutics has initiated the first clinical trial for gene-edited pig kidney transplants in humans, marking a significant advancement in this field [6] - The FDA's approval for this trial indicates a shift from individual cases to larger-scale clinical studies, reflecting technological maturity [6] Group 6: Macro and Industry News - Beijing's municipal government is supporting the development of the brain-computer interface industry with a dedicated incubation fund [6] - Shanghai's action plan aims to enhance efficiency in logistics through the application of drones in commercial settings [6] - The eighth Hongqiao International Economic Forum highlighted the importance of collaboration in humanoid robot technology development [6]

Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

Core Viewpoint - The article discusses the controversial emergence of companies focusing on gene editing technologies, particularly in relation to human embryos, highlighting the recent activities of Cathy Tie and her company Manhattan Genomics, as well as the ethical and safety concerns surrounding such advancements [2][10][11]. Company Overview - Cathy Tie, a Canadian entrepreneur, has founded multiple biotechnology companies over the past 11 years, including her latest venture, Manhattan Genomics, which aims to edit human embryo genes to prevent genetic diseases [4][8]. - Manhattan Genomics was co-founded by Cathy Tie and Eriona Hysolli, who previously worked at Colossal Biosciences, a company focused on resurrecting extinct species through gene editing [9][10]. Industry Developments - On October 30, 2025, Manhattan Genomics announced key employee hires, including a bioethicist and experts in non-human primate reproductive biology, as part of their preparation for potential CRISPR baby projects [10]. - Preventive, another company exploring gene editing in human embryos, recently secured nearly $30 million in funding, indicating a growing interest and investment in this controversial area [10]. Ethical and Safety Concerns - The scientific community largely agrees that commercializing gene editing in human embryos is premature, given the significant safety risks and ethical dilemmas compared to existing CRISPR therapies approved for conditions like sickle cell disease and β-thalassemia [11][12]. - Editing embryos poses unique challenges, as changes would affect nearly every cell in the body and could be passed on to future generations, raising unpredictable consequences [13]. Technological Context - CRISPR technology, recognized as a groundbreaking biotechnological advancement, received the Nobel Prize in Chemistry in 2020, yet its application in human embryos remains heavily restricted in many countries, including the U.S. [12]. - Recent advancements in gene editing for non-reproductive cells have progressed rapidly, with the first CRISPR-Cas9 therapy approved in 2023 for genetic blood disorders, showcasing the potential of gene editing outside of embryo manipulation [12].

相较于此前逆转录酶技术在哺乳动物细胞中仅1.5%的编辑效率，新技术将成功率提升至约30%。更值得 一提的是，该技术可通过脂质纳米颗粒包裹的RNA递送系统实现，有效规避了传统基因编辑器在递送 环节的难题。 目前，团队正运用该技术开发治疗囊性纤维化的基因疗法。这种疾病已知致病突变多达千余种。传统疗 法往往只能针对最常见突变进行优化，而新技术能直接替换整个缺陷区域，有望让更广泛的患者群体受 益。 （文章来源：科技日报） 由得克萨斯大学奥斯汀分校和犹他大学联合研发的这项新技术，不仅能同时修正哺乳动物细胞中的多种 致病突变，还成功治愈了斑马鱼胚胎中导致脊柱侧凸的突变。这是科学家首次运用逆转录酶技术，在脊 椎动物体内实现致病突变的精准修复，为人类疾病治疗开辟了新途径。 研究团队表示，现有基因编辑技术大多只能针对一两个特定突变，导致很多患者无法获得有效治疗。而 新技术能用健康DNA片段整体替换缺陷区域，如同为基因"打补丁"，可修复该片段内的任意突变组 合，不受个体遗传差异限制，让更多患者看到治愈希望。 美国科研团队在新一期《自然·生物技术》杂志发表研究成果称，他们基于逆转录酶开发出一种新型基 因编辑技术，能够更精准、更高效 ...